CD19-CD22 CAR-T cells

BIOLOGICAL3 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Shanxi Province Cancer Hospital

Conditions

Acute Lymphocytic Leukemia， B-CellLymphoma, B-CellRelapsed or Refractory B Cell Acute Lymphoblastic Leukemia

Early Phase 1

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

TerminatedNCT04034446

Institute of Hematology & Blood Diseases Hospital, ChinaRelapsed or Refractory B Cell Acute Lymphoblastic Leukemia

Start: 2019-09-30End: 2020-12-01Updated: 2025-06-03

Phase 1

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia

Shanxi Province Cancer HospitalAcute Lymphocytic Leukemia， B-Cell

Start: 2021-01-15End: 2023-12-31Target: 24Updated: 2021-01-22

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma

Shanxi Province Cancer HospitalLymphoma, B-Cell

Start: 2021-01-04End: 2025-10-31Target: 24Updated: 2023-12-29